Authors
Latest:
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From EndometriosisLearn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Latest:
Pelabresib in MPNs: Immune Profiles of Responders vs. Non-respondersPanelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).
Latest:
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple MyelomaLife After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Latest:
Optimization of Genetic Testing for mCRPCJason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Latest:
Oncology Peer Review On-The-Go: Characterization of Blood-Based Molecular Profiling in Pancreatic AdenocarcinomaChristine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Avelumab Maintenance for Urothelial Carcinoma: Real-World EvidenceDaniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With CancerABSTRACT Adolescents and young adults (AYAs) with cancer constitute approximately 70,000 patients diagnosed each year. Survival rates for AYAs with cancer have increased steadily in recent decades due to improvements in therapeutic regimens and early detection. Given the large and growing number of AYA cancer survivors, additional research is needed on the immediate and long-term psychosocial support required for this population including family planning and fertility. Fertility and fertility preservation in female AYAs, in particular, is historically understudied and has psychologically relevant ramifications distinct from male AYAs. Decision science can contribute to this area of oncological care and has implications for clinical encounters and research concerning female AYA patients with cancer. Patient-centered care and shared decision-making that integrates recent research regarding fertility preservation in the context of cancer treatment can improve outcomes for AYA cancer survivors.
Latest:
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual MeetingStephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Latest:
Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesIn this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.
Latest:
Revumenib Shows Efficacy and Safety in R/R KMT2Ar Acute LeukemiaRevumenib treatment results in durable MRD-negative remissions in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia in the phase 2 Augment-101 study.
Latest:
Key Takeaways on the Clinical Utility of ctDNA in Colorectal CancerStacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Using Genetic Information to Guide Precision Medicine and Personalized Treatment in Prostate Cancer: Expert Perspectives on an Evolving LandscapeDwight E. Heron, MD, MBA, FACRO, FACR discusses how advanced multi-omics approaches, personalized precision medicine techniques, artificial intelligence–driven genetic interpretation tools, and emerging gene editing technologies such as CRISPR (clustered regularly interspaced short palindromic repeats) are poised to revolutionize clinical practice by enabling more targeted diagnostics, predictive risk assessments, and individualized treatment strategies across oncology, rare disease management, and chronic condition prevention.
